Fundraising Fox

Scorpion Therapeutics

Boston, US · Founded 2020 · Delaware corporation · 10 known investors

Find your way into Scorpion Therapeutics

698 people in our graph share verified history with the Scorpion Therapeutics team — schools, employers, funds. One of them is your warm intro.

Wesley Chanunlockedknows Erica Jackson · together at Massachusetts Institute of Technology (overlapped)
×6knows the team · via Massachusetts Institute of Technology
knows the team · via University of Alberta
×4knows the team · via Brandeis University
Biotech

Founders & leadership

Scorpion Therapeutics was founded in 2020 by Adam Friedman and Gary Glick.

AFAdam Friedman
Adam FriedmaninCo-founder · President & CEO2024–2025Chief Executive Officer at Antares Therapeutics
GGGary Glick
Gary GlickinCo-founder
AFAndrew Fedder
Andrew FedderinGeneral Counsel2021–2025Executive Officer, Director at Antares Therapeutics
DSDarrin Stuart
Darrin StuartinChief Scientific Officer2020–2025Darrin Stuart is an oncology scientist with over 25 years of experience in cancer drug discovery and development. He previously led small molecule drug discovery projects at Novartis, including work on RAF kinase inhibitor programs, and translated preclinical research into clinical trial design and patient stratification strategies.
EJ
Erica JacksoninChief Discovery OfficerShe has experience in drug discovery and development across large and small molecules, with expertise in cancer biology including tumor heterogeneity, cancer stem cells, and mechanisms of drug resistance, as well as in vivo cancer modeling.
AV
Amanda ValentinoExecutive
PJ
Peter Joseph Campisi, Jr.Executive

Board

ONOleg Nodelman
Oleg NodelmaninBoard directorFounder and Portfolio Manager at EcoR1 Capital
OS
Otello StampacchiainBoard directorManaging Director at Omega Funds
SC
Shelley ChuBoard directorPromoter at Abingworth
JFJean-Francois Formela
Jean-Francois FormelainBoard directorPartner at Atlas Venture
SS
Saurabh SahaBoard director

Investors · 10

Atlas VentureCambridge · $500K – $1Mvia Jean-François Formela · board
Avoro Capital AdvisorsNew York
EcoR1 CapitalSan Franciscovia Oleg Nodelman · board
Frazier Life SciencesPalo Altovia Kevin Li · led
Nextech InvestZurich · $648K – $3.2M
Vida VenturesLos Angeles
AbingworthreportedLondon · $15M – $30M
Lightspeed Venture PartnersreportedMenlo Park · $1.7M – $87M
Olive Tree CapitalreportedBoston
Omega FundsreportedBoston

Reported raises · per SEC filings

Form D private placements

$297.4M disclosed across 3 of 4 rounds · 2020–2025

▶$125.7MraisedJul 2024 · 38 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew FedderExecutive Officer
  • Oleg NodelmanDirector
  • Otello StampacchiaDirector
  • Adam FriedmanExecutive Officer, Director
  • Shelley ChuDirector
  • Darrin StuartExecutive Officer
  • Erica JacksonExecutive Officer
  • Jean-Francois FormelaDirector
  • Amanda ValentinoExecutive Officer
  • Jeffrey AlbersDirector
  • Saurabh SahaDirector
  • Arjun GoyalDirector
  • Keith FlahertyDirector
  • Mark ChaoExecutive Officer
  • Brian PiperExecutive Officer
Offering amount
$150M
Amount sold
$125.7M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$147MraisedDec 2020 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jean-Francois FormelaDirector
  • Arjun GoyalDirector
  • Peter Joseph Campisi, Jr.Executive Officer
  • Keith FlahertyDirector
  • Otello StampacchiaDirector
  • Shelley ChuDirector
  • Gary GlickExecutive Officer, Director
Amount sold
$147M
First sale
Nov 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$24.7MraisedMay 2020 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gary GlickExecutive Officer, Director
  • Peter Joseph Campisi, Jr.Executive Officer
Amount sold
$24.7M
First sale
Apr 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Scorpion spinout raises $177M to advance preclinical assets after 2 clinical programs sold to Pierre Fabrefiercebiotech.com · Jun 2025Scorpion Tx Raises $150M For Cancer Pipeline with PI3Kα Inhibitor | Inside Precision Medicineinsideprecisionmedicine.com · Jul 2024Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipelinebusinesswire.com · Jul 2024Scorpion Therapeutics strikes major $162M funding round for 'precision oncology 2.0' | Fierce Biotechfiercebiotech.com · Jan 2021Scorpion Therapeutics Launches With $108 Million – ISPE Bostonispeboston.org · Nov 2020Scorpion Therapeutics Scores $108 Million Series A Funding for Oncological Research - GeneOnline Newsgeneonline.com · Oct 2020

Frequently asked questions

Who founded Scorpion Therapeutics?
Scorpion Therapeutics was founded by Adam Friedman, Gary Glick in 2020.
Who are Scorpion Therapeutics's investors?
Scorpion Therapeutics's investors include Atlas Venture, Avoro Capital Advisors, EcoR1 Capital, Frazier Life Sciences, Nextech Invest, Vida Ventures, Abingworth, Lightspeed Venture Partners and 2 more.
How much funding has Scorpion Therapeutics raised?
Scorpion Therapeutics has disclosed $297.4M raised across 3 of its 4 known rounds.
Where is Scorpion Therapeutics headquartered?
Scorpion Therapeutics is headquartered in Boston, US.